Over the next five years, ~ 4.5 million fractures are anticipated to occur in Brazil, Mexico, Colombia, and Argentina
LONDON-April 24, 2019
The financial cost required to help people with osteoporosis in Latin America is set to soar to $6.25 billion USD over five years, a study has found.
Published in The Journal of Medical Economics, this latest research has shown that in Brazil, Mexico, Colombia, and Argentina the financial burden of osteoporosis is expected to increase to more than $1 billion USD annually for the next seven years.
With 4.5 million fractures anticipated to occur over the next five years in these countries, the authors of the study have concluded there is a strong need to improve the diagnosis of osteoporosis and initiation of treatment for individuals at high fragility fracture risk in Latin America.
“The number of elderly people in Latin America is expected to double in the next 30 years, with corresponding increases in fracture incidence. There is a strong need to prevent this excess morbidity and mortality by initiating appropriate interventions. In the absence of intervention, the societal burden of osteoporosis will undoubtedly continue to grow,” said Rebecca McTavish from Cornerstone Research Group Inc.
The burden of illness study predicted that in 2018, 159,533 hip fractures and 840,239 total fractures (inclusive of hip) would occur among adults aged 50 to 89 in Brazil, Mexico, Argentina, and Colombia. The total number of fractures was predicted to increase by 14 percent in 2022 vs 2018, due to the aging populations in these four countries. Osteoporotic fractures among individuals aged 50 to 89 years are associated with a substantial economic cost.
The objective of “The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia and Argentina” was to quantify the current and future economic burden of osteoporosis in adults aged 50 to 89 years in these four Latin American countries.
It showed that the one-year burden of osteoporosis was highest in Mexico ($411 million USD), followed by Argentina ($360 million USD), Brazil ($310 million USD), and Colombia ($94 million USD). The one-year burden in all four countries was greatest due to hospitalization costs (36 percent), followed by productivity losses (30 percent), and surgical costs (23 percent). In Argentina, the largest proportion of the burden was attributable to surgical costs (42 percent), followed by hospitalization costs (33 percent). In Brazil, the largest proportion of the burden was attributable to productivity losses (61 percent), followed by hospitalization costs (19 percent). In Colombia, the largest proportion of the burden was attributable to productivity losses (37 percent), followed by hospitalization costs (28 percent). In Mexico, the largest proportion of the burden was attributable to hospitalization costs (51 percent). Cumulatively, testing and prescription medication costs accounted for only 8 percent and 4 percent of the burden, respectively.
The average burden per 1,000 people at risk in the four Latin American countries was $15,906 USD. When adjusting for the population at risk, the country with the greatest burden was Argentina ($32,583 USD), followed by Mexico ($16,671 USD), Colombia ($8,240 USD), and Brazil ($6,130 USD).
Despite the availability of a variety of treatment options, osteoporosis remains severely under-diagnosed and under-treated. Even when treated, non-persistence and non-compliance with current therapies such as bisphosphonates and other antiresorptives are common. It is estimated that only 24 percent of patients with fractures receive prescription drugs to help prevent refracture.
“To control and prevent these fractures, stakeholders must work together to close the care gap. Efforts to identify individuals at high fracture risk, initiate treatment, and improve long-term treatment persistence will be essential in minimizing the financial and patient burden of osteoporosis in Latin America,” said Dr. Chris Cameron from Cornerstone Research Group Inc.
The burden of illness study was carried out by Cornerstone Research Group Inc., an innovative health economic consultancy with expertise in evidence generation. It was supported by an unrestricted grant from Amgen, a leading biotechnology pioneer committed to bone health.
This study is available at: http://www.tandfonline.com/doi/full/10.1080/13696998.2019.1590843
Osteoporosis is a systemic skeletal disease that is characterized by low bone mass and deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Fragility fractures are the most serious consequence of osteoporosis, imposing a risk for loss of independence, chronic pain, the need for rehabilitation, and excess mortality. Osteoporosis imposes a very high burden on individuals, economies, and health systems worldwide. The global economic burden of osteoporosis is expected to rise to about $132 billion USD by 2050.
About Cornerstone Research Group
Cornerstone is a global health economic and market access research company supporting pharmaceutical and medical device companies. Founded in 2005, Cornerstone’s initial focus was to build on the Partners’ experience in health economic research with an emphasis on global cost-effectiveness models and Canadian reimbursement submissions. Since that time, the company has strategically grown to add a world-class evidence synthesis and data analytics team; develop outstanding payer communication capabilities; and support global programs with submissions in all major markets.
Cornerstone Research Group